Total
0
Shares
ScreenPro Security (CSE:SCRN) launches Rapid Antigen Testing with a mobile passport to get Canadians back to work
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ScreenPro Security (SCRN) launches Rapid Antigen Testing with a mobile passport to get Canadians back to work
  • This new antigen rapid test kit was approved by Health Canada on March 19
  • The addition of the rapid antigen test kit assists in ScreenPro achieving its goal to re-open businesses
  • ScreenPro provides turnkey coronavirus screening solutions to the private sector
  • ScreenPro, AKA, Compel Capital, (SCRN), is down 4 per cent and is trading at C$0.12 at close

Compel Security Inc. (SCRN) has added a Health Canada-approved antigen rapid test kit to its product offering.

Health Canada approved this new antigen rapid test kit on March 19.

Coupled with its current PCR testing services and the proposed acquisition of GoStop Inc.'s digital COVID passport announced on March 11, it provides ScreenPro with a complete suite of testing and screening tools and services for its clients.

The addition of the rapid antigen test kit assists in ScreenPro achieving its goal to re-open businesses and get all Canadians back to work and normal life.

John McMullen, CEO of ScreenPro, states, "I am pleased to report that our company has initiated the roll-out for rapid antigen and are processing tests now in both Ontario and Vancouver and will continue to expand our offering throughout our client base."

"If a person were to test positive, ScreenPro can then offer a second line of testing with its current PCR platform with 100% accuracy. If the patient requires a consultation, our medical team is also available to advise and consult with the client," added McMullen.

ScreenPro provides turnkey coronavirus screening solutions to the private sector. ScreenPro's unique access to multiple manufacturers of high-quality South Korean test kits and its strategic partnership with Canvas Labs in Vancouver and Integrated Explorations in Ontario.

This platform allows ScreenPro to be a nationwide provider of full-service testing solutions across Canada.

ScreenPro has its own pool of certified nursing and medical professionals, PPE and all ancillary products to ensure that its clients are protected in all aspects of their testing needs.

ScreenPro, AKA, Compel Capital, (SCRN) is down 4 per cent and is trading at C$0.12 at close.

More From The Market Herald
HempFusion (TSX:CBD.U) announces US$2M private placement

" HempFusion (TSX:CBD.U) increases private placement

HempFusion Wellness (CBD.U) has increased the size of its previously announced non-brokered private placement to over US$2,500,000.
Neovasc’s (TSX:NVCN) Reducer receives first national European reimbursement

" Neovasc (TSX:NVCN) announces FDA approval of clinical trial

Neovasc (NVCN) has received approval from the FDA for the Investigational Device Exemption regarding its COSIRA-II IDE Clinical Trial.
Relay Medical (CSE:RELA) & Fio to provide rapid COVID-19 testing at TIFF

" ScreenPro (CSE:SCRN) providing COVID-19 testing at TIFF

ScreenPro (SCRN) is providing COVID-19 testing services at this year’s Toronto International Film Festival.
Aurora Spine Corporation (TSXV:ASG) announces $6.5 million private placement

" Aurora Spine Corporation (TSXV:ASG) announces $6.5 million private placement

Aurora Spine Corporation (ASG) has announced a C$6.5 million private placement with institutional investors.